BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $27 to $24.
BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $27 to $24.